Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains Clear Data for Nivolumab & Ipilimumab | In the Frontline for Intermediate & Poor-Risk Patients at Annual Meeting 2018
Advertisement
Clear Data for Nivolumab & Ipilimumab | In the Frontline for Intermediate & Poor-Risk Patients
